Integer Holdings Earnings Call Flags Tough 2026

Integer Holdings ((ITGR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Integer Holdings’ latest earnings call painted a cautiously optimistic but undeniably mixed picture for investors. Management highlighted modest first‑quarter sales growth and strategic positives like share repurchases, lower interest costs, and a formal strategic review, yet these were overshadowed by pressure on margins, weaker cash flow, and a cut to full‑year 2026 guidance.

Q1 Revenue Edges Higher Despite Softer Environment

Integer reported Q1 2026 sales of $440 million, up 0.5% on a reported basis and 1.3% organically compared with a year ago. The modest top‑line increase signals that demand is holding up overall, even as certain pockets of the business, most notably electrophysiology, experience normalization after a period of rapid growth.

Core Cardio & Rhythm Businesses Still Growing

Cardio & Vascular revenue reached $262 million in Q1, rising 1% and bringing trailing four‑quarter sales in that segment to $1.11 billion, up 13%. Cardiac Rhythm Management & Neuromodulation delivered $168 million in Q1 sales, a solid 5% increase, with trailing four‑quarter revenue up 2% to $677 million, underscoring resilience in the company’s core med‑tech franchises.

Lower Interest and Buybacks Cushion EPS

Adjusted earnings per share came in at $1.20, benefiting meaningfully from financial levers rather than operating strength. A $4 million reduction in interest expense added about $0.10 per share, while $100 million of share repurchases across late 2025 and Q1 2026 trimmed the share count by roughly 2%, contributing around $0.02 to EPS.

Cost Cuts Aim to Stabilize Margins

To address profitability pressure, Integer is rolling out targeted cost reductions designed to avoid hurting customer service or long‑term growth initiatives. Management expects these actions to support an 80–140 basis‑point sequential improvement in adjusted operating margin in Q2, with further margin gains anticipated over the balance of 2026.

Leverage Stays Within Targeted Range

The company ended Q1 with net total debt of $1.264 billion, an increase of $74 million from the prior quarter largely due to share buybacks. Even with the uptick, net leverage stands at 3.2 times trailing four‑quarter adjusted EBITDA, which remains comfortably within Integer’s strategic target range of 2.5 to 3.5 times.

Board Launches Strategic Review to Unlock Value

In a notable development for shareholders, Integer’s board has initiated a strategic review following heightened external interest in the business. Management stressed its confidence in the stand‑alone strategy and long‑term goals, but the process opens the door to potential alternatives aimed at maximizing shareholder value.

Long‑Term Growth Theme Backed by Pipeline

Despite near‑term turbulence, management reiterated confidence in the underlying med‑tech markets, which are expected to grow 4%–6% annually. With a robust new product pipeline, Integer still targets a return to organic sales growth roughly 200 basis points above the market by 2027, signaling a belief that current headwinds are cyclical rather than structural.

Capital Allocation Prioritizes Growth and Buybacks

The company has been active in returning capital to shareholders, repurchasing about $100 million of stock between Q4 2025 and Q1 2026. For 2026, Integer plans capital expenditures of $95–$105 million, around 5%–6% of sales, while targeting free cash flow of $85–$105 million to support both investment and balance sheet flexibility.

Operating Margins Under Pressure

Beneath the modest revenue growth, profitability weakened meaningfully as adjusted operating income dropped 14% year over year. Adjusted operating margin contracted by 230 basis points to 13.9%, with management pointing primarily to lower fixed‑cost absorption as a key driver of the margin squeeze.

EBITDA and Net Income Trend Lower

Adjusted EBITDA fell to $85 million in Q1, down $7 million, or 7%, compared with the prior year. Adjusted net income declined 10% to $41 million, and adjusted EPS slipped 8%, illustrating that earnings pressure is broad‑based across the income statement despite the interest savings and reduced share count.

Cash Flow Soft Start to the Year

Cash generation also weakened, as operating cash flow in Q1 was $25 million, about $6 million lower than a year earlier. After $24 million of capital expenditures, free cash flow for the quarter was essentially flat at $1 million, leaving little excess cash to deploy beyond existing commitments.

2026 Outlook Trimmed on Revenue and Profit

Management cut its 2026 outlook, now projecting reported sales of $1.805–$1.835 billion, implying a 1%–3% decline year over year and organic sales flat to down 1%. Adjusted EBITDA is expected at $375–$399 million and adjusted operating income at $285–$305 million, both down from prior expectations, with adjusted EPS forecast between $5.83 and $6.40.

Product Launch Drag and Portfolio Risk Adjustments

Three new products are expected to create a 3%–4% headwind to 2026 reported growth, reflecting ramp and transition dynamics rather than demand loss. Integer also tightened assumptions across its portfolio, lowering the prior organic growth outlook excluding those products from 4%–6% to about 3%–4%, signaling a more cautious stance on near‑term performance.

EP Normalization Weighs on Second‑Half Expectations

Electrophysiology, a key driver of recent growth, is now seeing customer forecasts reset after rapid adoption of new pulsed‑field ablation technologies. Management expects this normalization to hit primarily in the second half of 2026 but described it as temporary and not linked to insourcing or supplier losses, though it was a major factor in the guidance cut.

Portfolio Pruning Adds Inorganic Drag

The company continues to reshape its portfolio, with the completed exit from the Portable Medical business expected to contribute roughly a 1% inorganic decline in 2026 sales. Combined with other market exits and manufacturing service changes, these moves are projected to reduce revenue by about $34–$36 million year over year but are positioned as strategic simplifications.

Debt Rises on Buybacks but Stays Controlled

Integer’s net total debt increased by $74 million in Q1, largely reflecting the $50 million share repurchase executed during the quarter. Even with this additional leverage, management reiterated that the company remains firmly within its leverage target band and expects year‑end net debt to trend modestly lower as cash generation improves.

Guidance Signals Tough 2026 Before Growth Reaccelerates

Updated 2026 guidance calls for modestly lower revenue and profit alongside planned margin improvement as cost actions take hold. Management expects cash from operations of $185–$205 million, free cash flow of $85–$105 million, and year‑end leverage within its 2.5–3.5 times goal, while positioning 2026 as a reset year ahead of a projected reacceleration by 2027.

Integer’s earnings call underscored a company balancing near‑term earnings and cash flow pressure against a still‑constructive long‑term growth story. For investors, the mix of softer guidance, active capital returns, and a newly announced strategic review sets up 2026 as a transitional year, with execution on cost, pipeline, and EP normalization likely to drive the next leg in the stock’s narrative.